428 related articles for article (PubMed ID: 30630956)
1. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety.
Blumenfeld AM; Tepper SJ; Robbins LD; Manack Adams A; Buse DC; Orejudos A; D Silberstein S
J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):353-360. PubMed ID: 30630956
[TBL] [Abstract][Full Text] [Related]
2. Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine.
Blumenfeld AM; Aurora SK; Laranjo K; Papapetropoulos S
BMC Neurol; 2015 Jul; 15():100. PubMed ID: 26133547
[TBL] [Abstract][Full Text] [Related]
3. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
[TBL] [Abstract][Full Text] [Related]
4. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
[TBL] [Abstract][Full Text] [Related]
5. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
Lipton RB; Varon SF; Grosberg B; McAllister PJ; Freitag F; Aurora SK; Dodick DW; Silberstein SD; Diener HC; DeGryse RE; Nolan ME; Turkel CC
Neurology; 2011 Oct; 77(15):1465-72. PubMed ID: 21956721
[TBL] [Abstract][Full Text] [Related]
6. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
Ahmed F; Gaul C; García-Moncó JC; Sommer K; Martelletti P;
J Headache Pain; 2019 Mar; 20(1):26. PubMed ID: 30845917
[TBL] [Abstract][Full Text] [Related]
7. Fatigue, sleep-wake pattern, depressive and anxiety symptoms and body-mass index: analysis in a sample of episodic and chronic migraine patients.
Lucchesi C; Baldacci F; Cafalli M; Dini E; Giampietri L; Siciliano G; Gori S
Neurol Sci; 2016 Jun; 37(6):987-9. PubMed ID: 26879311
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
Blumenfeld AM; Patel AT; Turner IM; Mullin KB; Manack Adams A; Rothrock JF
J Prim Care Community Health; 2020; 11():2150132720959936. PubMed ID: 32985341
[TBL] [Abstract][Full Text] [Related]
9. Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study.
Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
J Headache Pain; 2019 Jan; 20(1):10. PubMed ID: 30669961
[TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
Aurora SK; Dodick DW; Diener HC; DeGryse RE; Turkel CC; Lipton RB; Silberstein SD
Acta Neurol Scand; 2014 Jan; 129(1):61-70. PubMed ID: 24107267
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study.
Winner PK; Blumenfeld AM; Eross EJ; Orejudos AC; Mirjah DL; Adams AM; Brin MF
Drug Saf; 2019 Aug; 42(8):1013-1024. PubMed ID: 31102144
[TBL] [Abstract][Full Text] [Related]
12. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.
Lipton RB; Rosen NL; Ailani J; DeGryse RE; Gillard PJ; Varon SF
Cephalalgia; 2016 Aug; 36(9):899-908. PubMed ID: 27288354
[TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
15. Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: A single-center prospective cohort study.
d'Onofrio F; de Falco A; Costanzo A; Spitaleri D; Casucci G; Raimo S
J Clin Neurosci; 2020 Oct; 80():152-155. PubMed ID: 33099338
[TBL] [Abstract][Full Text] [Related]
16. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
[TBL] [Abstract][Full Text] [Related]
17. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
[TBL] [Abstract][Full Text] [Related]
18. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
19. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
20. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU
Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
